181 related articles for article (PubMed ID: 19149492)
1. HCN channels as targets for drug discovery.
Maher MP; Wu NT; Guo HQ; Dubin AE; Chaplan SR; Wickenden AD
Comb Chem High Throughput Screen; 2009 Jan; 12(1):64-72. PubMed ID: 19149492
[TBL] [Abstract][Full Text] [Related]
2. HCN pacemaker channels and pain: a drug discovery perspective.
Wickenden AD; Maher MP; Chaplan SR
Curr Pharm Des; 2009; 15(18):2149-68. PubMed ID: 19519450
[TBL] [Abstract][Full Text] [Related]
3. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and pain.
Dunlop J; Vasilyev D; Lu P; Cummons T; Bowlby MR
Curr Pharm Des; 2009; 15(15):1767-72. PubMed ID: 19442189
[TBL] [Abstract][Full Text] [Related]
4. Involvement of hyperpolarization-activated, cyclic nucleotide-gated cation channels in dorsal root ganglion in neuropathic pain.
Wan Y
Sheng Li Xue Bao; 2008 Oct; 60(5):579-80. PubMed ID: 18958363
[TBL] [Abstract][Full Text] [Related]
5. Hyperpolarization-activated and cyclic nucleotide-gated channel proteins as emerging new targets in neuropathic pain.
He JT; Li XY; Zhao X; Liu X
Rev Neurosci; 2019 Jul; 30(6):639-649. PubMed ID: 30768426
[TBL] [Abstract][Full Text] [Related]
6. Functional impact of the hyperpolarization-activated current on the excitability of myelinated A-type vagal afferent neurons in the rat.
Zhou YH; Sun LH; Liu ZH; Bu G; Pang XP; Sun SC; Qiao GF; Li BY; Schild JH
Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):852-61. PubMed ID: 20456426
[TBL] [Abstract][Full Text] [Related]
7. Testing broad-spectrum and isoform-preferring HCN channel blockers for anticonvulsant properties in mice.
Kharouf Q; Pinares-Garcia P; Romanelli MN; Reid CA
Epilepsy Res; 2020 Dec; 168():106484. PubMed ID: 33099130
[TBL] [Abstract][Full Text] [Related]
8. HCN channels and heart rate.
Scicchitano P; Carbonara S; Ricci G; Mandurino C; Locorotondo M; Bulzis G; Gesualdo M; Zito A; Carbonara R; Dentamaro I; Riccioni G; Ciccone MM
Molecules; 2012 Apr; 17(4):4225-35. PubMed ID: 22481543
[TBL] [Abstract][Full Text] [Related]
9. HCN channels: function and clinical implications.
Benarroch EE
Neurology; 2013 Jan; 80(3):304-10. PubMed ID: 23319474
[TBL] [Abstract][Full Text] [Related]
10. Exploring HCN channels as novel drug targets.
Postea O; Biel M
Nat Rev Drug Discov; 2011 Nov; 10(12):903-14. PubMed ID: 22094868
[TBL] [Abstract][Full Text] [Related]
11. Hyperpolarization-activated cation channels: from genes to function.
Biel M; Wahl-Schott C; Michalakis S; Zong X
Physiol Rev; 2009 Jul; 89(3):847-85. PubMed ID: 19584315
[TBL] [Abstract][Full Text] [Related]
12. HCN1 channels as targets for anesthetic and nonanesthetic propofol analogs in the amelioration of mechanical and thermal hyperalgesia in a mouse model of neuropathic pain.
Tibbs GR; Rowley TJ; Sanford RL; Herold KF; Proekt A; Hemmings HC; Andersen OS; Goldstein PA; Flood PD
J Pharmacol Exp Ther; 2013 Jun; 345(3):363-73. PubMed ID: 23549867
[TBL] [Abstract][Full Text] [Related]
13. Cardiac HCN channels: structure, function, and modulation.
Biel M; Schneider A; Wahl C
Trends Cardiovasc Med; 2002 Jul; 12(5):206-12. PubMed ID: 12161074
[TBL] [Abstract][Full Text] [Related]
14. HCN and KV7 (M-) channels as targets for epilepsy treatment.
Shah MM; Huang Z; Martinello K
Neuropharmacology; 2013 Jun; 69():75-81. PubMed ID: 22446478
[TBL] [Abstract][Full Text] [Related]
15. Hyperpolarization-activated cyclic-nucleotide-gated channels potentially modulate axonal excitability at different thresholds.
Weerasinghe D; Menon P; Vucic S
J Neurophysiol; 2017 Dec; 118(6):3044-3050. PubMed ID: 28904107
[TBL] [Abstract][Full Text] [Related]
16. Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay.
Lee YT; Vasilyev DV; Shan QJ; Dunlop J; Mayer S; Bowlby MR
Eur J Pharmacol; 2008 Feb; 581(1-2):97-104. PubMed ID: 18162181
[TBL] [Abstract][Full Text] [Related]
17. Hyperpolarization-activated, cyclic AMP-gated, HCN1-like cation channel: the primary, full-length HCN isoform expressed in a saccular hair-cell layer.
Cho WJ; Drescher MJ; Hatfield JS; Bessert DA; Skoff RP; Drescher DG
Neuroscience; 2003; 118(2):525-34. PubMed ID: 12699787
[TBL] [Abstract][Full Text] [Related]
18. Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy.
Resta F; Micheli L; Laurino A; Spinelli V; Mello T; Sartiani L; Di Cesare Mannelli L; Cerbai E; Ghelardini C; Romanelli MN; Mannaioni G; Masi A
Neuropharmacology; 2018 Mar; 131():403-413. PubMed ID: 29339292
[TBL] [Abstract][Full Text] [Related]
19. HCN-related channelopathies.
Baruscotti M; Bottelli G; Milanesi R; DiFrancesco JC; DiFrancesco D
Pflugers Arch; 2010 Jul; 460(2):405-15. PubMed ID: 20213494
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic role of I(f) revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (HCN) channels.
Xue T; Siu CW; Lieu DK; Lau CP; Tse HF; Li RA
Circulation; 2007 Apr; 115(14):1839-50. PubMed ID: 17389267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
